NCT07665879RecruitingPhase 1
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 145 (estimated)
- First submitted
- 10 Mar 2026
- Start date
- 9 Jun 2026
- Lead sponsor
- Eli Lilly & Co.
- Diseases
- Obesity
- EU CT number
- 2025-523873-41-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 145
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH Coordinator of this site? Confirm its status | Neuss | Germany | Recruiting |
| CTC Clinical Trial Consultants AB Coordinator of this site? Confirm its status | Moelndal | Sweden | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.